NYSE:VOR Vor Biopharma (VOR) Stock Price, News & Analysis $0.23 +0.01 (+3.20%) Closing price 06/4/2025 04:00 PM EasternExtended Trading$0.23 +0.00 (+0.13%) As of 08:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Vor Biopharma Stock (NYSE:VOR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Vor Biopharma alerts:Sign Up Key Stats Today's Range$0.22▼$0.2350-Day Range$0.15▼$0.7652-Week Range$0.13▼$1.80Volume1.26 million shsAverage Volume1.02 million shsMarket Capitalization$28.58 millionP/E RatioN/ADividend YieldN/APrice Target$7.06Consensus RatingHold Company OverviewVor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More… Vor Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreVOR MarketRank™: Vor Biopharma scored higher than 73% of companies evaluated by MarketBeat, and ranked 260th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingVor Biopharma has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 4 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageVor Biopharma has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vor Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Vor Biopharma are expected to grow in the coming year, from ($1.42) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vor Biopharma is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vor Biopharma is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.45% of the float of Vor Biopharma has been sold short.Short Interest Ratio / Days to CoverVor Biopharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vor Biopharma has recently decreased by 15.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.45% of the float of Vor Biopharma has been sold short.Short Interest Ratio / Days to CoverVor Biopharma has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vor Biopharma has recently decreased by 15.27%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News SentimentN/A News SentimentVor Biopharma has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Vor Biopharma this week, compared to 1 article on an average week.Search Interest9 people have searched for VOR on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.MarketBeat Follows3 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Vor Biopharma is held by insiders.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vor Biopharma's insider trading history. Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address VOR Stock News HeadlinesVor Bio details extent of Cambridge layoffs in state filingJune 2 at 4:07 PM | bizjournals.comVor Biopharma Inc. Advanced Charts - Barron'sMay 29, 2025 | barrons.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.June 5, 2025 | Priority Gold (Ad)Stifel cuts Vor Biopharma stock rating amid clinical and financial concernsMay 10, 2025 | investing.comJMP Securities Downgrades Vor Biopharma (VOR)May 10, 2025 | msn.comVor Biopharma draws downgrades on strategic reviewMay 9, 2025 | msn.comJones Trading cuts Vor Biopharma stock rating to HoldMay 9, 2025 | investing.comHC Wainwright & Co. Downgrades Vor Biopharma (VOR)May 9, 2025 | msn.comSee More Headlines VOR Stock Analysis - Frequently Asked Questions How have VOR shares performed this year? Vor Biopharma's stock was trading at $1.11 at the start of the year. Since then, VOR stock has decreased by 79.4% and is now trading at $0.2287. View the best growth stocks for 2025 here. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NYSE:VOR) posted its earnings results on Thursday, November, 7th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $150 million in an initial public offering on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO. Who are Vor Biopharma's major shareholders? Vor Biopharma's top institutional shareholders include Jane Street Group LLC (0.16%), Exchange Traded Concepts LLC (0.12%), OMERS ADMINISTRATION Corp (0.11%) and Goldman Sachs Group Inc. (0.07%). View institutional ownership trends. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vor Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vor Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Ford Motor (F), Pfizer (PFE), Bank of America (BAC) and General Motors (GM). Company Calendar Last Earnings11/07/2024Today6/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological Products, Except Diagnostic Substances Sub-IndustryPharmaceutical Products Current SymbolNYSE:VOR CIK1817229 Webwww.vorbiopharma.com Phone617-655-6580FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$7.06 High Stock Price Target$14.00 Low Stock Price Target$0.40 Potential Upside/Downside+2,985.8%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares124,960,000Free Float65,446,000Market Cap$28.58 million OptionableNot Optionable Beta-0.51 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NYSE:VOR) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredThe Real Reason Silver Prices Are SoaringElon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Social Security Changes No One’s Talking AboutWhile most Americans worry about their next Social Security check... something far bigger is happening behind ...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.